Cisplatin remains the standard treatment for head and neck cancer, but in roughly half of patients the tumor returns because of acquired resistance. Alongside this work in the archive are studies that also seek ways around resistance: one paper examines why cells die differently under neutron irradiation, another builds a mathematical model for kidney cancer. Both neighboring works move toward personalized therapy selection, but this article takes a step further: it does not merely describe a resistance mechanism, it proposes a specific two-stage treatment scheme that uses cellular senescence itself as a target.
The researchers took paired head and neck squamous cell carcinoma cell lines: the original HN30 and Detroit-562, along with their variants grown in the constant presence of cisplatin (HN30R and Detroit-562R). Cells were treated with sacituzumab govitecan (SG), and senescence was then assessed by beta-galactosidase activity, the appearance of p21 and secretory factors. To test the role of the TROP2 target, lines with suppressed TROP2 were used. Apoptosis was measured by flow cytometry with annexin V, and the role of BAX and BAK was tested using a double knockdown. In mouse experiments, HN30R cells were injected into the cheek of immunodeficient animals, followed by SG and ABT-263 according to the schedule.
Both cell pairs proved sensitive to SG, and the cisplatin-resistant lines HN30R and Detroit-562R were not inferior to their parental lines: the half-maximal inhibitory concentration was 0.2–1 µg/mL. SG induced senescence in 35–60% of cells, and in the resistant HN30R line the fraction of senescent cells was higher, correlating with elevated TROP2 levels. Suppressing TROP2 reduced senescence induction. SN-38 alone, the cytotoxic component of the conjugate, induced senescence in 45% of cells, whereas the "naked" antibody did not. Sequential treatment with SG followed by ABT-263 or A-1155463 (both inhibit BCL-XL) led to the death of 30–60% of cells according to annexin V, while the BCL-2 inhibitor ABT-199 produced no such effect. Double knockdown of BAX and BAK completely abolished apoptosis induced by the combination but did not affect senescence induction. In mouse experiments, the combination of SG and ABT-263 significantly slowed tumor growth and increased survival compared with SG or ABT-263 monotherapy, and the animals' body weight did not decrease.
The work shows that senescence induced by an antibody-drug conjugate can be used as a point of attack for a senolytic. Unlike neighboring studies that either describe cell death mechanisms or build predictive models, here a specific sequential scheme is proposed and tested in a living organism. This is the first demonstration for head and neck cancer that the combination of SG and ABT-263 works against cisplatin-resistant cells by eliminating the senescent population. Such an approach could become the basis for clinical trials in patients with tumor relapse.
The field may move toward safer senolytics, since ABT-263 causes thrombocytopenia and is unsuitable for long-term use. Derivatives have already appeared, such as DT2216, which selectively degrade BCL-XL and are in early clinical trials. Further work could test the combination of SG with such agents, and also examine whether this scheme works in virus-positive head and neck cancer, where TROP2 levels do not differ from virus-negative tumors.
The results matter for oncology, especially for the treatment of head and neck cancer, and also for the development of combination schemes with antibody-drug conjugates and senolytics in other solid tumors.
The next step is to test the combination of SG and ABT-263 on virus-positive head and neck cancer lines, and then move to preclinical trials with safer BCL-XL inhibitors such as DT2216.
The work directly addresses the unsolved problem of acquired chemoresistance in oncology. It shows that cellular senescence arising after therapy is not a dead end but can be used as a therapeutic target. This changes the view of senescence as a mechanism of tumor escape and offers a concrete way to overcome it.
Sacituzumab govitecan is FDA-approved for metastatic triple-negative breast cancer, but in head and neck cancer trials as a single agent it showed only a modest effect. This work explains why: cells enter senescence and temporarily "fall asleep," then return to dividing. Adding a senolytic prevents them from waking up.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.